There are Merck clinical trials in progress. Find a Merck trial. Medical advances can only happen through these scientific and voulnteer efforts.
Diversity in our clinical trial research Different people may have different reactions to the same treatment, based on their age, gender, weight, race, ethnicity, and other factors. Clinical trials rely on volunteers to take part, and it’s vital that these volunteers come from diverse background...
Diversity in our clinical trial research Different people may have different reactions to the same treatment, based on their age, gender, weight, race, ethnicity, and other factors. Clinical trials rely on volunteers to take part, and it’s vital that these volunteers come from diverse background...
Monitoring Excellence, Site Development/Engagement & Trial Diversity (MESD) Develops strategy and site monitoring tools and processes to position our company as the partner of choice. Risk Evaluation & Adaptive Integrated Monitoring Furthers the organization’s risk-based quality management through advance...
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck...
Congrats to the team on their achievement! The completion of the clinical Phase III trial brings hope to the most vulnerable populations affected by this devastating worm disease. Jutta Reinhard-Rupp,Global Health Institute, Switzerland Contribution to our strategic goal 1 ...
Users can choose from conservative, balanced, or aggressive investment strategies, enabling them to select an option that best matches their comfort with market fluctuations. This diversity is essential in today is unpredictable economic landscape, allowing investors to navigate different market conditions ...
September 25, 2024 · 155 min read · BioSpace Editorial Staff Podcast Novo Grilled By Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval September 25, 2024 · 1 min read · Heather McKenzie Layoffs Bluebird Bio to Lay Off 25% of Workforce ...
I'm pleased by the continued progress with these programs and our growing diversity across new therapeutic areas and modalities. Along these lines, we're particularly excited by our recently announced clinical and commercial collaboration with Daiichi Sankyo for three potentially first-in-class antib...
(PDE) 2A1 as well as PDE4A1A and PDE4D2. Phosphodiesterase inhibition itself is associated with a variety of pharmacological effects, and PDE inhibitors are available as medicaments for the treatment of a diversity of conditions, including depression, multiple sclerosis and chronic obstructive ...